In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
08 SEP 2023 | Coherus Completes Acquisition Of Surface Oncology Coherus Biosciences announced that it completed its acquisition of Surface Oncology, Inc., a clinical-stage...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
01 SEP 2023 | AU | Celltrion Submits Marketing Application For CT-P43, Biosimilar To Janssen’s Stelara® (Ustekinumab) Business Korea reported that Celltrion filed an application...
25 AUG 2023 | US | Celltrion and J&J Reach Patent Settlement Regarding Ustekinumab Korea Biomedical Review reported that Celltrion has finalised an agreement with Johnson...
18 AUG 2023 | US | FDA Approves Regeneron’s 8mg Eylea® (Aflibercept) For wAMD, DME and DR Regeneron announced that the FDA approved its 8mg Eylea® (aflibercept) to treat Wet...
12 AUG 2023 | US | Biocon Confirms Viatris North American Transition Will Complete By End Q3 2023 According to the Business Standard Biocon Biologics’ CEO has confirmed the...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
We are pleased to announce that 3 Pearce IP leaders are ranked amongst the world’s best patent and trade mark practitioners by WIPR Leaders 2023. Pearce IP’s Executives Naomi...
03 AUG 2023 | US | Teva confirms intention to launch US adalimumab biosimilar AVT02 in 2024 Teva’s CEO confirmed that it will still pursue launching its Alvotech...
27 JUL 2023 | EU | New indication alert: AZ’s Soliris® (eculizumab) approved to treat gMG in children aged six to 17 AstraZeneca announced that the EMA has approved Soliris®...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
21 JUL 2023 | EU | CHMP adopts positive opinion for three biosimilars The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
We are excited to announce that Naomi Pearce, (CEO, Executive, Lawyer, Patent & Trade Mark Attorney), founder of Pearce IP, was crowned the 2023 Intellectual Property...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
14 JUL 2023 | EU | EMA confirms acceptance of Intas’ MAA for its ustekinemab (Stelara®) biosimilar Intas Pharmaceuticals announced that the European Medicine Agency (EMA) has...
We are proud to announce that Naomi Pearce, (Executive, Lawyer, Patent & Trade Mark Attorney), founder of Pearce IP, is a finalist for the award of Intellectual Property...
Australian and New Zealand patent examiners typically frown upon the use of trade marks in claims. Primarily, a trade mark is a sign that denotes origin, and a trade mark-branded...
07 JUL 2023 | IN | CuraTeQ Biologics enters into exclusive licence agreement with BioFactura, Inc to commercialise its biosimilar to Janssen’s Stelara® (ustekinumab) Aurobindo...
Boutique IP firm Pearce IP announces the promotion of Patent & Trade Mark Attorney Dr Chris Vindurampulle to Executive, with effect from 1 July 2023. Founder and CEO Naomi...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
We are delighted to announce that Pearce IP, together with three of its leaders have been ranked in IAM Patent 1000 in 2023. IAM Patent 1000 “shines a spotlight on the firms and...
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
01 JUL 2023 | US | Organon and Samsung Bioepis announce launch of Hadlima®, biosimilar to AbbVie’s Humira® (adalimumab) Organon and Samsung Bioepis announced that Hadlima®,...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
